SHC014748M, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

Abstract

PI3Kδ (phosphatidylinositol 3-kinase-δ), one of the class I PI3Ks, is found expressed primarily in leukocytes and plays an essential role in B-cell development and function. This provides a rationale for the development of small molecule inhibitors that selectively target p110δ for patients with indolent non-Hodgkin lymphomas. Here in this paper, we comprehensively evaluated the in vitro and in vivo antitumor activity of SHC014748M, an oral selective inhibitor of PI3Kδ under Phase I clinical evaluation. Biochemical and cell-based assays were used to measure compound potency and selectivity in lymphoma cell lines as well as primary chronic lymphocytic leukemia (CLL) cells. Scid mice were subcutaneously inoculated with the SU-DHL-6 cell line. SHC014748M was more selective for PI3Kδ inhibition relative to other class I PI3K enzymes and showed in vitro activity in most of 23 B lymphoma cell lines and primary CLL cells. SHC014748M also inhibited phosphorylation of AKT, targets downstream of PI3Kδ, in both lymphoma cells and primary CLL cells. In vivo study revealed that SHC014748M significantly reduced lymphoma cell growth in the treatment group compared with control mice. CCL4, CCL17, CCL22 and CXCL13 in patient serum decreased sharply after SHC014748M treatment. According to the results, SHC014748M appeared to be a novel promising compound in the treatment of B cell lymphomas and CLL.

Keywords: PI3Kδ, Inhibition, SHC014748M, Preclinical, Lymphoma

Background

Non-Hodgkin lymphomas (NHL) is a heterogeneous group of solid tumors of the lymphatic system, nearly 90% of which arise from B lymphocytes [1–3]. In 2015, approximately 88,200 people were diagnosed with lymphoma, among which 80%—90% are NHL, while approximately 52,100 died of lymphoma in China [4–6]. Nearly one third of NHLs are indolent while the others are aggressive [7,8]. Indolent NHL...
Phosphatidylinositol 3-kinase (PI3Ks) are enzymes that mediate signals from cell surface receptors with a central role in regulation of cell metabolism, proliferation and survival. The class I PI3Ks contain 4 isoforms, named PI3Kα, β, δ, and γ. PI3Kα and β are expressed ubiquitously, while PI3Kδ is preferentially expressed in leukocytes [17–19]. PI3K δ is expressed mainly in the cells of hematopoietic lineage, where it integrates and transmits signals from surface proteins including B-cell antigen receptors (BCRs) and chemokine receptors (CXCR4 and CXCR5) responsible for cell homing and retention in tissue compartments, via downstream activation of AKT (Protein kinase B). AKT is a central node in signaling cascades that regulate cell survival, proliferation and migration, which is also known to activate the pro-growth mammalian target of rapamycin complex [20–22]. PI3Kδ inhibition targets proliferation, migration and survival of malignant B-cell leukemia and lymphoma cells, whereas PI3K γ inhibition reduces the differentiation and migration of key cells in the tumor microenvironment, such as CD4+ T cells and M2 tumor-associated macrophages, which sustain leukemia and lymphoma cells in a protective niche [23–25].

Since 2018, the Food and Drug Administration (FDA) has approved 3 PI3K inhibitors for iNHL treatment, namely Idelalisib, Duvelisib, and Copanlisib. Idelalisib is the first p110δ-selective inhibitor used for relapsed or refractory CLL in combination with rituximab, relapsed, or refractory FL after 2 lines of prior therapies and relapsed or refractory SLL after 2 lines of prior therapies. In a cell-based assay, GS-1101 inhibited PI3Kδ signaling with an EC₅₀ of 8.9 nM. The IC₅₀ was 19 nM in vitro assays using recombinant protein. And in a kinase screen, idelalisib inhibited other Class I PI3K isoforms between 83% and 97.3%. In vitro assays demonstrate that GS-1101 is between 110- and 453-fold more selective for inhibition of PI3Kδ [26]. However, Idelalisib has a black box warning on its product label regarding the risks of fatal and serious toxicities including hepatic toxicity, severe diarrhea, colitis, pneumonitis, infections and intestinal perforation [27,28]. Duvelisib is different from Idelalisib as it targets both p110δ and p110γ. In September 2018, Duvelisib received its first approval for the treatment of adult patients with relapsed or refractory CLL/SLL at least 2 lines of prior therapies. But it also has a black box warning regarding the risks of fatal and serious toxicities including severe diarrhea, colitis, pneumonitis, infections and cutaneous reaction [29,30]. Copanlisib has predominant inhibition against PI3Kα and PI3Kδ isoforms, which has been proved by FDA for the treatment of patients with relapsed FL after at least 2 prior systemic therapies [31]. Although these treatments approved by FDA showed encouraging efficacy for iNHL, serious adverse drug reactions are difficult to avoid. Other PI3K inhibitors such as Umbralisib, INCB050465, ME-401, RP-6530, ACP-319, Pictilisib, Acalisib, and KA-2237 are still under clinical development [32].

From the studies conducted so far, novel oral drugs with improvements in safety and long-term maintenance are still needed. SHC014748M is a small-molecule inhibitor of PI3K with high selectivity to δ isoform. Here, we present the preclinical characterization of SHC014748M as single-agent in vitro and in vivo tumor models of lymphomas and CLL. This trial is registered with ClinicalTrials.gov, number NCT03588598.

**Methods**

**Compounds**

SHC014748M was provided by Sanhome Therapeutics (Nanjing, China). Its molecular formula is C23H21CIN6O4S while its structural formula is given in Figure 1. Idelalisib was purchased from Shining Pharmaceutical Technology Co., Ltd (Shandong, China).

**B cell lymphoma cell lines**

A total of 23 human lymphoma cell lines (from ATCC and he Cell Bank of the Chinese Academy of Sciences) were used 1 (SU-DHL-2) from activated B cell like diffuse large B-cell lymphoma (ABC DLBCL), 8 (DB, Pfeiffer, OCI-LY-19, SU-DHL-4, SU-DHL-6, WSU-DLCL2, TOLEDO, DOHH2) from germinal center B cell DLBCL (GCB DLBCL), 4 (GRANTA-519, MINO,REC-1 and Z-138) from mantle cell lymphoma (MCL), 10 (NAMALWA, CA46, RAJI, DAUDI, ST486, P3HR-1, GA-10, EB2, EB1, Ramos-2G6-4C10) from Burkitt’s lymphoma. Cell lines were cultured in RPMI 1640 medium (INVITROGEN, Cat #61870127) supplemented with 10% fetal bovine serum (GIBCO, Cat #10099-141), and incubated at 37 °C/5% CO₂. All cell lines have been authenticated using STR profiling within the last 3 years and the cells are free of mycoplasma.

**Primary CLL cells**

Peripheral blood samples were obtained from CLL patients in Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University). The study was approved by the Institutional Review Board of Jiangsu Province Hospital and was conducted in accordance with Declaration of Helsinki. CLL cells were isolated by B Cell Isolation Kit (Miltenyi Biotec, Cat #130091151) and were cultured at 37 °C/5% CO₂ for 24 hours.

**In vitro kinase activity assay**

In vitro enzymatic activity was measured using Mobility Shift Assay, Lance Ultra Assay, Lance Screen Assay, Kinases-Glo Assay and ADP-Glo Assay. Kinases were purchased from BPS, Carna, Invitrogen, Millipore and ProQimase. Kinases were seeded in 384-well plates and treated with ten different concentrations of each compound (ranging between 0.05 nM and 10 μM) in duplicate. Staurosporine was used as positive control. Fluorescence polarization were read by Envision 2104 Multilabel (PERKINELMER INC). The 50% inhibitory concentration (IC₅₀) was calculated by fitting the dose-response curve to a 4-parameter log-logistic equation respectively.
Cell proliferation inhibition assay

Human lymphoma cell lines were seeded in 96-well plates and treated with 9 different concentrations of each compound (ranging between 3 nM and 20 μM) in duplicate. Cells were then incubated for 72 hours at 37 °C, 5% CO₂. Primary CLL cells were seeded in 96-well plates and treated with 6 different concentrations of each compound (ranging between 100 nM and 100 μM) in duplicate. Dimethyl sulfoxide (DMSO) was added to negative control (untreated) cells alone. Wells containing medium only were included on each plate as blanks for absorbance readings. CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat # G7572, Cat # G7573) was used to measure cell proliferation. IC₅₀ was calculated by fitting the dose-response curve to a 4-parameter log-logistic equation respectively.

Cell apoptotic assay

The percentages of viable and apoptotic lymphoma cell line cells [Annexin V positive/7-Aminoactinomycin D (7-AAD) negative and Annexin V positive/7-AAD positive] were determined by double staining WSU-NHL cells with Annexin V-FITC/7-AAD. Cells were treated with 3 different concentrations of each compound (ranging between 30 nM and 300 nM) in triplicate, then harvested and resined with cold phosphate-buffered saline (PBS) once. After centrifugation for 5 minutes, cells were resuspended in 500 μL of 1× Annexin V binding buffer (Biolegend, Cat # 640934) and then added with 5 μL of PE Annexin V (Biolegend, Cat # B210905) and 5 μL of 7-AAD viability staining buffer (Biolegend, Cat # B219262). After incubation for 15 minutes at room temperature in the dark, the samples were analyzed by flow cytometry.

Cell-based assay

Raji and PC-3 cells were cultured in RPMI Medium 1640 with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C, 5% CO₂. RAW264.7 and C2C12 cells were cultured in DMEM medium with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C, 5% CO₂. P3Kδ-specific RAJI cells were stimulated with 3 μg/mL F(ab)₂ anti IgM (Jackson ImmunoResearch, Cat # 109006129) for 10 minutes. P13Kδ-specific C2C12 cells were stimulated with 1200 ng/mL insulin like growth factor 1 (IGF-1, Invitrogen, Cat # PHG0078) for 20 minutes. P13Kδ-specific PC-3 cells were stimulated with 15 μg/mL Lysophosphatidic acid (LPA, SIGMA-ALDRICH, Cat # L7260) for 20 minutes. P13Kδ-specific RAW 264.7 cells were stimulated with 80 ng/mL C5a (Biotang, Cat # RPR9899) for 5 min. Then cells were treated with ten different concentrations of SHC014748M in triplicate. Phosphorylation of AKT in cells was determined using AlphaLISA technology from PerkinElmer.

AlphaLISA

CLL cells were cultured in 96-well plates with various concentrations of SHC014748M or Idelalisib for 30 min, then stimulated by Anti-Human IgM F (ab)² (SIGMA-ALDRICH, Cat # SAB3701394) for 10 minutes. pAKT was measured by AlphaLISA pAKT Kit (PERKINELMER INC, Cat # ALSU-PAKT-B500) and AlphaLISA AKT1 Kit (PERKINELMER INC, Cat # ALSU-TAKT1-A500).

In vivo experiments

Animal experiments were performed under the Guide of animal care and use (NCR 2011) and the Chinese National Standard (GB149252010) without blinded conduct. Scid (CB17 SCID) mice (Ling Chang Biotechnology Co., Ltd, Shanghai, China) were subcutaneously inoculated with the SU-DHL-6 cell line (1 × 10⁷ cells in 0.2 mL of RPMI 1640, 1:1 matrigel). When tumors were palpable, mice were randomly (based on tumor size) assigned into the SHC014748M treatment groups receiving 50 mg/kg, 100 mg/kg, or 200 mg/kg once daily. Idelalisib treatment groups receiving 100 mg/kg or 200 mg/kg once daily and the control group receiving vehicle alone once daily (n = 9 in each group to achieve the power of test). Caliper measurements of the longest perpendicular tumor diameters were performed every 2 days to estimate the tumor volume (vmm² = D x d²/2). Treatments were started when tumor volumes reached approximately 150 mm³. Tumor size was measured using a digital caliper from the first day of treatment until day of first death. Compounds was dissolved in 1% carboxyl methylcellulose/0.5% Tween 80 and stored at 4 °C for in vivo study.

Western blotting analysis

Cells were solubilized in hot sodium dodecyl sulfate lysis buffer and sonicated for 15 seconds. The protein contents were determined using the bicinchoninic acid protein assay. Lysates were fractionated by 8% sodium dodecyl sulfate-PAGE. Membranes were incubated with primary antibodies overnight, followed by the appropriate horseradish peroxidase-conjugated antiamino or antirabbit secondary antibodies for 1 hour. After that, members were scanned by Odyssey imaging system (LI-COR Biosciences). Equal loading of samples was confirmed by probing for Actin. The following antibodies were used: P13Kinase p110δ (1D1Q7R) Rabbit mAb (CST, Cat # 34050); The TM β actin Antibody Mouse mAb (Genscript, Cat # A00702100); IRDye 800CW Goat anti-Rabbit IgG (H + L) (Li-COR, Cat # 92632211); IRDye 800CW Goat anti-Mouse IgG (H + L) (Li-COR, Cat # 92632210).

Measurement of chemokine concentrations using ELISA

The effects of SHC014748M on CCL4, CCL17, CCL22, and CXCL13 secretion was measured in blood sample of patients receiving 150 mg QD or 200 mg QD. Coated antibody solution was added to each well in duplicate. After 12 hours, the supernatant of each well was harvested and assayed for CCL4, CCL17, and CXCL13 protein by quantitative ELISA according to the manufacturer’s instructions (R&D Systems, CAS # P161174).

Pharmacokinetic assessments

Blood samples for measurement of SHC014748M and Idelalisib concentrations were collected at the following time points: prior to and at 10, 30, 60, 120, 360, 600, and 1440 minutes after the start of study drug administration on days 1 and 14. Immediately following withdrawal of Heparin sodium-anticoagulated blood. Blood samples were centrifuged at 4500 rpm for 10 minutes at 4 °C and plasma samples were stored at −20–80 °C until analysis. SHC014748M concentrations were determined by a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay. A tandem mass spectrometer was used for the detection of the compounds, and quantification was based on the peak area ratios of compound and its stable isotope labelled internal standard. Concentrations below the limit of quantification were not included in the PK analyses.

Data analysis and statistics

Results are expressed as mean or mean ± standard error of mean (SEM) or mean ± SD. Statistical analysis was performed using GraphPad Prism version 4.00 for Windows. Analysis of variance was used for comparison among groups, Student’s paired or unpaired t test was used for comparison between groups. P < 0.05 was considered statistically significant.
Table 1

SHC014748M is a potent PI3Kδ inhibitor with highly selectivity against other class I PI3K isoforms.

| Kinase | PI3Kδ | PI3Kα | PI3Kβ | PI3Kγ |
|--------|-------|-------|-------|-------|
| IC50 (nM) | 0.77 | 236 | 96 | 101 |
| Fold-selectivity | 1x | 306x | 125x | 131x |

Results

SHC014748M is a highly selective PI3Kδ inhibitor

To determine the selective inhibition of SHC014748M, evaluation against a panel of 50 different kinases which are closely related to BCR signal were conducted. Among 50 kinases, SHC014748M inhibited the activity of all 4 Class I PI3K isoforms. IC50 of PI3Kδ, PI3Kα, PI3Kβ, and PI3Kγ are respectively 0.77, 236, 96, and 101 nM. SHC014748M was 125- to 306-fold more selective for PI3Kδ inhibition compared with other class I PI3K isoforms (Table 1). Inhibition curves of SHC014748M against class I PI3K isoforms were shown in Figure 2A. No significant inhibition was observed against the other 46 diverse protein kinases with 10 μM of SHC014748M (data not shown).

SHC014748M exerts antitumour activity in B cell lymphoma cell lines in vitro

The effects of SHC014748M (ranging between 3 and 20 μM) on cell proliferation were evaluated on 23 B cell lymphoma cell lines. IC50 of SHC014748M varies from 27 nM to over 20 μM respectively, showing in vitro activity in most of them with a median IC50 value of 7383 nM. SHC014748M produced more robust inhibition on cell proliferation in GCB DLBCL cell lines with a median IC50 value of 4790 nM, while showed less activity in highly invasive MCL cell lines with a median IC50 value of 12,850 nM (Figure 2B). Idelalisib had weak antiproliferative activity in most of the B cell lymphoma cell lines with IC50 values of over 20 μM. According to the results above, SHC014748M is a highly selective PI3Kδ inhibitor with more potent antitumor activity in lymphoma cells compared to Idelalisib in vitro.

SHC014748M concentration-dependently promotes apoptosis in a B cell lymphoma cell line in vitro

The functional role of PI3Kδ was evaluated by measuring apoptosis in WSU-NHL cell line, exposed concentrations from 30 to 3000 nM. As shown in Figure 2C and D, SHC014748M at the concentration of 30 nM led to a 2.4-fold increase (Control, 4.9%; SHC014748M, 12.0%) in the proportion of apoptotic cells in Annexin V+/7-ADD+ staining, whereas a 3.7-fold increase (Control, 5.2%; SHC014748M, 19.1%) in annexin V+/7-ADD- staining, indicating that both early stage apoptosis and late stage apoptosis were significantly induced by SHC014748M even at the minimum concentration. We also found that, SHC014748M at the concentration of 30, 300, and 3000 nM resulted in 3.1-, 4.2-, and 5.5-fold increase (Control, 10.1%; 30 nM, 31.1%; 300 nM, 42.1%, 3000 nM, 55.7%) in the total apoptotic cells respectively, showing that SHC014748M could induce apoptosis in B cell lymphoma cells in a concentration-dependent manner. Idelalisib exhibited comparable induction of apoptotic cell death as SHC014748M at the concentration of 300 nM and 3000 nM, but its efficacy at 30 nM was much lower than that of SHC014748M (1.7-fold vs. 3.1-fold).

SHC014748M selectively inhibits phosphorylation of class I PI3K isoform-dependent AKT in vitro

To determine the cellular selectivity of SHC014748M against the Class I PI3K isoforms, inhibition of phosphorylation of AKT was measured. PI3Kα activity was reflected by pAKT in IGF-1 stimulated C2C12 cells, while PI3Kβ was reflected by pAKT in LPA stimulated PC-3 cells, PI3Kγ was reflected by pAKT in C5a stimulated RAW264.7 cells and PI3Kδ was reflected by pAKT in anti- IgM stimulated Raji cells. The results in Figure 2E showed that SHC014748M potently inhibited phosphorylation of AKT, specific downstream of PI3Kδ, on threonine-308 or serine-473 (IC50 = 3.32 nM). On the other hand, no significant inhibition was observed against AKT phosphorylation in other Class I PI3K; IC50 of pAKT in PI3Kα is >30,000 nM (>9036-fold vs PI3Kδ); IC50 of pAKT in PI3Kβ is 453.3 nM (137-fold vs PI3Kα) and IC50 of pAKT in PI3Kγ is 3040 nM (916-fold vs PI3Kδ). Idelalisib inhibited pAKT of PI3Kδ as potent as SHC014748M (IC50 = 5.55 nM), whereas its selectivity was much lower: IC50 of pAKT in PI3Kα is >30,000 nM (>5405-fold vs PI3Kδ); IC50 of pAKT in PI3Kβ is 380.3 nM (69-fold vs PI3Kδ) and IC50 of pAKT in PI3Kγ is 1123 nM (202-fold vs PI3Kδ). Thus, in cell-based assays, SHC014748M had 137- to >9036-fold selectivity for PI3Kδ over the other class I PI3K isoforms while Idelalisib had 69- to >5405-fold selectivity.

SHC014748M shows antitumor activity in primary CLL cells in vitro

To confirm the in-vitro antitumor activity of SHC014748M on CLL, the viability of primary leukemia cells derived from CLL patients were determined by Cell Titer-Glo Assay, exposed concentrations from 3.0 nM to 10 μM. SHC014748M showed in vitro efficacy in most of the primary CLL cells, with the IC50 values varied from 850 nM to 37,040 nM. As illustrated in Figure 3A, the IC50 values of SHC014748M in 12 CLL cells were less than 20 μM while in 3 CLL cells were beyond 20 μM. IC50 of Idelalisib varied from 25,650 nM to >200,000 nM respectively, which are much higher than that of SHC014748M (Figure 3A). According to the results above, SHC014748M had more potent antitumor activity in primary CLL cells compared with Idelalisib.

PI3Kδ is highly expressed in primary CLL cells

Given the importance of PI3Kδ signaling in B-cell development, we sought to determine the protein expression of PI3Kδ in primary CLL cells in patient serum. As the results shown in Figure 3B and C, in CLL samples derived from 6 different patients, high expression of PI3Kδ was found with relatively little variability among patients. In addition to primary CLL cells, we also evaluated the expression profile of PI3Kδ in normal B cells and Raji cell line, a lymphoblast-like derived cell line from Burkitt’s lymphoma. As expected, the protein level of PI3Kδ in Raji cell line was as abundant as that in primary CLL cells, whereas much higher than that in normal B cells.

AKT phosphorylation was decreased by SHC014748M in primary CLL cells

To corroborate our in vitro findings in isoform-specific cell-based assay, the pAKT levels in circulating CLL cells with and without SHC014748M treatment was evaluated by AlphaLISA. Not surprisingly, the phosphorylation of AKT was rapidly raised after anti-IgM stimulation and decreased in the presence of SHC014748M or Idelalisib at the concentration ≥100 nM. SHC014748M at the concentration ≥100 nM could efficiently decrease the levels of pAKT to the unstimulated levels, comparing with Idelalisib only at the concentration ≥300 nM (Figure 3D and E).
Figure 2. SHC014748M, a novel selective inhibitor of PI3Kδ and downstream AKT signaling, exerted antitumor activity in lymphoma cell lines in vitro. (A) The inhibition curves versus the concentration of SHC014748M against class I PI3K isoforms PI3Kδ, PI3Kα, PI3Kβ, and PI3Kγ were obtained by fitting the data (ranging between 0.05 nM and 10 μM) to a 4-parameter log-logistic equation in duplicate. Data are presented as mean ± SEM. (B) Cell viability was determined by performing CellTiter-Glo Luminescent Cell Viability Assay in lymphoma cell lines after SHC014748M treatment for 72 hours. IC₅₀ were calculated by fitting the dose-response curves (ranging between 3 nM and 20 μM) to a 4-parameter log-logistic equation respectively. (C) Representative stained cells after treatment with DMSO, STS and 30, 300, 3000 nM of SHC014748M for 48 hours were tested using annexin V/7-ADD staining assay and followed by flow cytometric analysis. Q1: cell debris; Q2: late stage apoptotic cells (annexin V+/7-ADD+); Q3: early stage apoptotic cells; (annexin V+/7-ADD-) Q4: live cells (annexin V-/7-ADD-). (D) Qualitative analysis of the percentage ratios of viable, apoptotic, and necrotic cells in SHC014748M and Idelaslisib treated WSU-NHL cells. (E) AKT phosphorylation was determined by AlphaLISA. Plot the Alpha signal read on Envision against the concentration of SHC014748M ranging between 0 and 3000 nM for RAJI cells, and 0 nM and 100 μM for PC-3, RAW 264.7, and C2C12 cells. Data are presented as mean ± SEM. STS, Staurosporine; PI3K, phosphatidylinositol 3-kinase.
Figure 3. SHC014748M shows antitumor activity in primary CLL cells in vitro. (A) Cell viability was determined by performing CellTiter-Glo Luminescent Cell Viability Assay in lymphoma cell lines after SHC014748M treatment for 24 hours. IC_{50} were calculated by fitting the dose-response curves (ranging between 100 nM and 100 μM) to a 4-parameter log-logistic equation respectively. (B) CLL cells from patients, normal B cells from healthy persons and Raji cell line were examined for PI3Kδ expression by Western blot. Normal B cells were isolated from PBMC of 20 healthy persons. β-actin was served as a loading control. (C) The bar diagram represents relative expression of PI3Kδ. The expression of PI3Kδ in normal B cells were regarded as 100%. (D) Anti-IgM was used to activate BCR signal in CLL cells in the presence or absence of SHC014748M or Idelalisib. Cells were lysed and AKT phosphorylation was determined by AlphaLISA. (E) The bar diagram represents the inhibition rate of SHC014748M or Idelalisib at different concentrations. CLL, chronic lymphocytic leukemia.
concentration of dosing. Accumulation multiple were pharmacokinetic model body the more Idelalisib groups were represented Figure 720 cells. The observed with time pharmacokinetic profile of SHC014748M and Idelalisib in vivo xenografts model on (C) Day 1 and (D) Day 14. Data are represented as mean ± SEM. * means P < 0.05.

**SHC014748M exhibited in vivo antitumor activity in lymphoma**

The in vivo efficacy of SHC014748M was next evaluated by xenograft model in which SCID mice are injected subcutaneously with SU-DHL-6 cells. SHC014748M reduced tumor growth in all treatment groups and showed statistically significant differences in tumor volume between the control group versus SHC014748M treatment groups (50, 100, vs 200 mg/kg; P < 0.05, Figure 4A), so did the Idelalisib treatment groups (100 mg/kg, 200 mg/kg; P < 0.05). Significant differences in tumor weight were also found between the control group versus all SHC014748M treatment groups (50 mg/kg, 100 mg/kg, 200 mg/kg; P < 0.05, Figure 4B) and Idelalisib 100 mg/kg treatment group (P < 0.05), while SHC014748M has more potent antitumor activity than Idelalisib at the dose of 200 mg/kg. At the same time, treatment with either does of SHC014748M did not affect the body weight (data not shown). Taken together, these data demonstrated that SHC014748M significantly inhibits lymphoma cell growth in mice xenograft model in vivo.

The pharmacokinetic parameters on days 1 and 14 in this SCID mice xenograft model are summarized in Table 2. Concentration-time pharmacokinetic profiles are illustrated in Figure 4C. C_max for SHC014748M were observed at 1 hour indicating rapid absorption after single dose and multiple doses. C_max and AUC(0-24h) demonstrated only slight increases in exposure above the level of 50 mg for SHC014748M repeated dosing. Accumulation ratio (mean ratio of Day 14/Day 1 AUC) was 1.54 for QD dosing. Mean apparent terminal elimination half-life (t1/2) following 14 days of dosing ranged from 6.5 to 11.7 hours. In addition, as expected, blood concentration of SHC014748M in SCID mice was higher than the effective concentration obtained in-vitro study (Figure 4A).

**SHC014748M inhibits secretion of the chemokines and cytokines in iNHL patients**

To confirm our findings in the preclinical study, we evaluated the concentrations of CCL4, CCL17, CCL22 and CXCL13 in iNHL patients before and after treatment with SHC014748M. As illustrated in Figure 5, secretion of CCL4, CCL17, CCL22 and CXCL13 in blood samples from 6 patients (3 from the 150 mg QD group and 3 from 200 mg QD group) were significantly inhibited after the oral administration of SHC014748M. The respective mean CCL4, CCL17, CCL22 and CXCL13 concentrations of patients before taking drugs were 124.4, 315.1, 3799.3, and 734.5 pg/mL, which are comparable with the reference [33]. Durative treatment of patients with SHC014748M once a day for 14 days remarkably abrogated the secretion of CCL4, CCL17, CCL22 and CXCL13, reducing the respective mean values for CCL4, CCL17, CCL22, and CXCL13 to 81.9, 35.9, 971.8, and 184.3 pg/mL. Levels of CCL4, CCL17, CCL22, and CXCL13 remained the same after treatment of SHC014748M once a day for 28 days. SHC014748M showed nearly universal reductions in concentrations of circulating chemokines and cytokines in iNHL patients. The presence or levels of any one or any combination of the chemokine biomarkers CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, and tumour necrosis factor (TNF)-alfa can be used to select a patient with a hematological disorder for treatment [34]. A key spot of this paper is the evaluation of chemokines, such as CCL4, CCL17, and CCL22, that tie together BCR signaling and the lymph node microenvironment [35]. We demonstrated a remarkable inhibition of CCL4, CCL17, and CCL22 production in patients treated with SHC014748M. These data corroborated that CCL4, CCL17, and CCL22 might function as surrogate markers of B cell activation, and hence may...
also function as markers for response to therapy. Plasma concentrations of circulating CXCL13, a chemokine that attracts B cells to lymph nodes [36], among patients receiving SHC014748M was substantially reduced. Loss of CXCL13 production may be particularly important in explaining the lymphocytosis observed during early treatment with drug.

**Discussion**

In this paper, we have shown that (1) SHC014748M, a novel PI3Kδ inhibitor, is potently effective and highly selective in both kinase assay and isoform specific cell-based assay; (2) Cell proliferation is inhibited by SHC014748M not only in B cell lymphoma cell lines but also in primary CLL cells; (3) expression of AKT phosphorylation decreases because of SHC014748M treatment in B cell lymphoma cell line as well as primary CLL cells; (4) SHC014748M promotes apoptosis of lymphoma cell line in a concentration-dependent manner; (5) SHC014748M has antilymphoma activity in SU-DHL-6 xenograft model. (6) SHC014748M administration inhibits secretion of the chemokines and cytokines in patients.

Based upon basic medical research and strong preclinical data, intensive efforts have been made to develop PI3K inhibitors for the treatment of iNHL [37,38]. Idelalisib is a potent, orally bioavailable PI3K inhibitor that is specific for the δ isoform, approved by FDA for the treatment of CLL and
FL. PI3K inhibitors approved by FDA also include Duvelisib, which inhibit both the PI3Kα and γ isoforms, and Copanlisib, which is a combined PI3K α/δ inhibitor. Other PI3K inhibitors such as Umbralisib, INCB050465, ME-401, RP-6530, ACP-319, Pictilisib, Acalisib, KA-2237 and DaxibotulinumtoxinA have also been seen. However, the exact role of PI3K in the adverse reactions remains unclear and efforts should be made to alleviate the adverse reaction [29,41]. SHC014748M was found to have a lethal dose of 200 mg/kg in SD rats, and a maximum tolerated dose of 60 mg/kg. The main side-effects of SHC014748M were gastrointestinal reactions and bone marrow toxicity, and the target organ sites of toxicity included adrenal, bone marrow (sternum and femur), immune organs (mesenteric lymph nodes, spleen, and thymus), liver, and stomach. Pneumonia was a major adverse effect in the Phase I trial of SHC014748M involving tNHL patients. Most of the adverse side effects are thought to be consequences of on-target inhibition in T cells, producing both susceptibility to infections and autoimmune effects, so there may be no reason to think that a highly-specific PI3K-γ inhibitor will fare better [41].

There are 8 mammalian PI3K enzymes, which are grouped into 3 classes [42,43]. The most important in cancer are the 4 class I enzymes, termed PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ [44,45]. Among which p110α and p110β are widely expressed by all cell types while p110γ and p110δ are expressed primarily in hematopoietic cells and have important roles in the functions of both innate and adaptive immune cells [46,47]. Bi et al. have generated p110α- and p110β-deficient mice, both of which die as embryos, after embryonic day (E) 9.5 or shortly after implantation, respectively. Besides, PI3Kδ inhibition was found to cause hyperglycemia and hypertension in clinical trial [48,49]. Sasaki et al. showed that T-cell development and function were impaired, whereas B cells were unaffected, in p110γ-deficient mice [50,51]. Considering the above information, we aim to improve the in-vitro selectivity of SHC014748M against other PI3K class I isoforms. The results of kinase assay showed that, SHC014748M was 125- to 306-fold more selective for PI3Kδ inhibition relative to other PI3K class I enzymes. In the cell-based assay, SHC014748M was strongly potent against PI3Kδ and highly selective versus PI3Kδ/γ (>900 ×), with ~137 × selectivity versus PI3Kβ. This result is in accordance with the result in kinase assay and shows that SHC014748M has achieved our ultimate goal.

NHL is a heterogeneous group of human lymphoid malignancies of primarily B-cell lineage (B-NHL) that appear to correspond to various stages in normal B-cell ontogeny [39]. These lymphomas from low-grade (indolent) to high-grade (aggressive) histotypes that correspond in part to various cellular proliferation indices (flow cytometry, cell cycle analysis, tumor growth fraction, labeling index, etc.) of the lymphoma cells [52,53]. Thus, efficacy of drugs differs among NHL subtypes in clinical research. As a result, we evaluated SHC014748M in 23 B cell lymphoma cell lines and primary CLL cells. The results of the experiment showed that SHC014748M produced more robust inhibition on cell proliferation in GCB DLBCL cell lines with a median IC50 value of 4790 nM, while showed less effects in highly aggressive MCL cell lines with a median IC50 value of 12,850 nM. In 15 primary CLL cells, SHC014748M showed in vitro antiproliferation activity in most of them. The results above would help to figure out the potential clinical indications of SHC014748M.

INHL is a group of B cell malignancies which are characterized by slow-progression so that it is difficult to establish an animal model with long disease duration for drug validation. Considering that proliferation of SU-DHL-6 could be remarkably inhibited by SHC014748M in vitro study, SU-DHL-6, an aggressive B cell lymphoma cell line, was used to establish the mouse model of B cell lymphoma. The results of the experiment showed that

### Table 3

| Kinase inhibition assays of SHC014748M and other PI3K inhibitors. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Compound**    | **Kinase**      | **IC50(nM)**    | **Fold-selectivity** |
| SHC014748M      | IC50 (nM)       | 0.77            | 1x               |
|                 | Fold-selectivity| 236             | 306x             |
|                 |                 | 96              | 125x             |
|                 |                 | 101             | 131x             |
|                  | SHC014748M      | 19              | 8600             |
|                  | Fold-selectivity| 453X            | 210X             |
|                  |                 | 110X            | 2100             |
|                  | SHC014748M      | 2.5             | 1602             |
|                  | Fold-selectivity| 640X            | 34X              |
|                  |                 | 11X             | 27               |
|                  | SHC014748M      | 0.7             | 0.5              |
|                  | Fold-selectivity| 3.7             | 5X               |
|                  |                 | 6.4             | 9X               |

### Table 4

| Antitumor activities of SHC014748M and Copanlisib in vitro.  |
|-----------------|-----------------|-----------------|-----------------|
| **Classification** | **cell line** | **IC50 (nM)** | **Copanlisib** | **SHC014748M/ Copanlisib** |
| ABC DLBCL       | Pfeiffer        | 4641.98         | 0.849          | 546758                 |
|                  | OCI-LY19       | 9957.66         | 1994           | 4.99                   |
|                  | Toledo          | 3210.91         | 3498           | 0.92                   |
|                  | WSU-DLCL2       | 784.00          | 123.4          | 6.35                   |
SHC014748M administration delayed tumor growth at all dosage. However, there were no differences of tumor volume among the 3 doses. Possible reason for this may be that 50 mg/kg may be the saturation dose of SHC014748M in SCID mice. Besides SHC014748M at the dose of 50 mg/kg might achieved the maximum antitumor effect in this aggressive lymphoma model. According to the pharmacokinetic results, exposure of SHC014748M was much higher than Idecalisib at the same dosage. It might be because that SHC014748M was more metabolic stable than Idecalisib in liver microsome of mice (data not shown).

Phase I study has been developed with SHC014748M as a single agent in patients with relapsed or refractory indolent B cell NHL, including CLL, MZL, FL, and Waldenström's macroglobulinemia (NCT03588598). In the Dose escalation trial, SHC014748M exhibits an acceptable safety profile in patients treated up to 3 months. Steady-state concentration, a pharmacokinetic parameter which seems to be closely related to efficacy according to the clinical research of Idecalisib [54,55], of SHC014748M in patients at the dose above 150 mg/day are far higher than the concentration which is effective in preclinical in-vitro study.

In conclusion, SHC014748M, a novel selective PI3Kδ inhibitor, presents promising antitumor activity in iNHL.

CRediT authorship contribution statement

Lei Fan: Conceptualization, Supervision, Methodology, Writing - review & editing.
Chao Wang: Software, Data curation, Writing - original draft.
Liwen Zhao: Data curation, Investigation, Visualization.
Zhiqiang Wang: Software, Data curation, Validation.
Xian Zhang: Software, Formal analysis, Validation.
Xiaorong Liu: Software, Data curation, Validation.
Lei Cao: Data curation, Investigation, Visualization.
Wei Xu: Project administration, Supervision, Writing - review & editing.
Jianyong Li: Project administration, Funding acquisition, Supervision, Writing - review & editing.

Acknowledgments

We wish to thank all the patients who took part in this research, their families, and the investigators.

References

[1] Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848–57. doi:10.1016/S0140-6736(12)60605-9.
[2] Chiu BC, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res 2015;165:1–25. doi:10.1007/978-3-319-13150-4_1.
[3] SEERSEER Stat Fact Sheets: Non-Hodgkin lymphoma. Bethesda, MD: National Cancer Institute; 2012.
[4] Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. doi:10.3322/caac.21338.
[5] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29. doi:10.3322/caac.21208.
[6] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebeco M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86. doi:10.1002/ijc.29210.
[7] Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurcak WJ, Flihn IW, Flowers CR, Martin P, Vaidot A, et al. PI3Kδ inhibition by idecalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008–18. doi:10.1056/NEJMoa1314583.
[8] Boweyk AA, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ 2018;362:k3204. doi:10.1136/bmj.k3204.
[9] Lunnning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012;26:279–88. doi:10.1016/j.blr.2012.09.004.
[10] Swedlow F. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. ed4th. Lyon: International Agency for Research on Cancer; 2008.
[11] Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. J Clin Oncol 2018;36:2259–66. doi:10.1200/JCO.2017.76.3656.
[12] Flinn IW, Patel M, Oki Y, Horwitz S, Foss FE, Allen K, Douglas M, Stern H, Sweeney J, Khadrija J, et al. Duvelisib, an oral dual PI3Kδ,γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol 2018;93:1311–17. doi:10.1002/ajh.25228.
[13] National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN Guidelines): B-cell lymphomas (version 1.2017). Available online: https://www.nccn.org.
[14] Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs 2018;27:513–22. doi:10.1080/13543784.2018.1482273.
[15] Horning SJ. Natural history of and therapy for the indolent non-Hodgkin lymphomas. Semin Oncol 1993;20:75–88.
[16] Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015;33:2516–22. doi:10.1200/JCO.2014.59.7534.
[17] Fung-Leung WP. Phosphoinositide 3-kinase δ (PI3Kδ) in leukocyte signaling and function. Cell Signal 2011;23:603–8. doi:10.1016/j.cellsig.2010.10.002.
[18] Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isofoms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 2019;20:515–34. doi:10.1038/s41580-019-0129-z.
[19] Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012;13:195–203. doi:10.1038/nrm3290.
[20] Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–74. doi:10.1016/j.cell.2007.06.009.
[21] Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O’Brien S, Yu A, Miller LL, et al. The phosphoinositide 3-kinase δ inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–12. doi:10.1182/blood-2011-05-352492.
[22] Vanhaesebroeck B, Guillerme-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329–41. doi:10.1038/nrm2882.
[23] Kaneda MM, Messer KS, Kalainithina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 2016;539:437–42. doi:10.1038/nature19834.
[24] De Henau O, Rausch M, Winkler D, Campuzano LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 2016;539:443–7. doi:10.1038/nature20554.
[25] Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isofoms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 2019;20:515–34. doi:10.1038/s41580-019-0129-z.
[26] Center for Drug Evaluation and Research: Application Number: 205858Orig1s000. Available online: https://www.fda.gov/drugs.
[27] ZYDELIG (idelalisib tablets) Gilead Sciences, Inc.; Foster City, CA: 2014. Full prescribing information. Available online: https://www.fda.gov/media/100575/download.
[28] Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslofski A, Smith SE, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma:
the alliance for clinical trials in oncology A051201 and A051202 phase I trials. *Lancet Haematol* 2017;4:e176–82. doi: 10.1016/S2355-3026(17)30028-5.

[29] Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? *Nat Rev Clin Oncol* 2018;15:273–91. doi: 10.1038/nrclinonc.2018.28.

[30] Flinn IW, O’Brien S, Kuhl B, Patel M, Oki Y, Foss FE, Porcu P, Jones J, Burger JA, Jain N, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ, -γ, is clinically active in advanced hematologic malignancies. *Blood* 2018;131:877–87. doi: 10.1182/blood-2017-05-786566.

[31] Eltantawy A, Vallejos X, Sebea E, Evans K, Copanilis. An intravenous phosphatidinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma. *Ann Pharmacother* 2019;53:954–8. doi: 10.1177/1060028019833992.

[32] Rodgers TD, Reagan PM. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. *Expert Opin Emerg Drugs* 2018;23:111–22. doi: 10.1080/14728214.2018.1479396.

[33] Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O’Brien SM, Faderl S, Kornblau SM, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. *Blood* 2011;118:3489–98. doi: 10.1182/blood-2011-03-339077.

[34] Methods of Treating Hematological Disorders with Quinazolinone Compounds in Selected Subjects. 2011.

[35] Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. *Blood* 2009;113:3050–8. doi: 10.1182/blood-2008-07-170415.

[36] Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. *Blood* 2007;110:3316–25. doi: 10.1182/blood-2007-05-089409.

[37] Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov* 2014;13:140–56. doi: 10.1038/nrd4204.

[38] Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. *Expert Opin Investig Drugs* 2017;26:1267–79. doi: 10.1080/13543784.2017.1384815.

[39] Barrientos JC. I德尔alibis for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. *Onco Targets Ther* 2016;9:2945–53. doi: 10.2147/OTT.S102573.

[40] Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. *Curr Opin Cell Biol* 2017;45:62–71. doi: 10.1016/jceb.2017.02.007.

[41] Esposito A, Viale G, Curigliano G. Safety, tolerability, and management of toxic effects of phosphatidinositol 3-kinase inhibitor treatment in patients with cancer: a review. *JAMA Oncol* 2016. doi: 10.1001/jamaoncol.20190034.

[42] Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isofrom-specific PI3K signalling. *Nat Rev Mol Cell Biol* 2010:329–41. doi: 10.1038/nrm2882.

[43] Hirsch E, Ciraolo E, Franco I, Ghigo A, Martin M. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. *Oncogene* 2014;33:3083–90. doi: 10.1038/onc.2013.265.

[44] Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbach M, Stamp G, Downward J, BAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. *Cell* 2013;153:1050–63. doi: 10.1016/j.cell.2013.04.031.

[45] Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. *Curr Opin Oncol* 2006;18:77–82. doi: 10.1097/01.cop.0000198021.99347.b9.

[46] Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond. *Nat Rev Immunol* 2007;7:191–201. doi: 10.1038/nri2036.

[47] Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. *Oncogene* 2008;27:5511–26. doi: 10.1038/onc.2008.246.

[48] Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphatidinositol-3-kinase. *J Biol Chem* 1999;274:10963–8. doi: 10.1074/jbc.274.16.10963.

[49] Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110δ catalytic subunit of PI 3-kinase. *Mamm Genome* 2002;13:169–72. doi: 10.1007/BF02684023.

[50] Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Irie A, Bouchard D, Kozieradzki I, et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. *Science* 2000;287:1040–6. doi: 10.1126/science.287.5455.1040.

[51] Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. *Immunol Rev* 2009;228:253–72. doi: 10.1111/j.1600-065X.2008.00750.x.

[52] Bryant J, Pham L, Yoshimura L, Tamayo A, Ordóñez N, Ford RJ. Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models. *Lab Invest* 2000;80:557–73. doi: 10.1038/labinvest.3780061.

[53] Cabanillas F, Rivera N, Pardo WI. Indolent lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis. *Clin Lymphoma Myeloma Leuk* 2016;16:550–7. doi: 10.1016/j.clml.2016.08.011.

[54] Flinn IW, Kuhl B, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Couteur SE, Benson DM, Pettermann S, et al. Idealalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. *Blood* 2014;123:3406–13. doi: 10.1182/blood-2013-11-535746.

[55] Brown JR, Byrd JC, Couteur SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kuhl B, Belo C, Webb HK, et al. Idealalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. *Blood* 2014;123:3390–7. doi: 10.1182/blood-2013-11-535047.